Earnings
The Swedish firm is plotting the path towards launching its ColdZyme virus-blocking spray in China and Japan, while efforts are also underway to find a partner for the North American market.
Energy, immunity and women's health supplements were in particular demand in 2024, according to French self-care industry association NèreS.
As Norway's Orkla Health searches for a new CEO, the business looks well-placed for future growth after a 15% uplift in sales in 2024.
Navamedic is seeing good early sales for OTC ED treatment Eroxon in multiple Nordic markets after investing in a marketing push which includes a Mission Impossible-inspired commercial.
PCH announces 2.7 % reported growth to $290.3m in revenues for its latest quarter. Fleet line extensions don’t the brand against fiber product lines such as Metamucil and Benefiber. Licenses all markets for Hydralyte outside US. Two more Clear Eyes suppliers to be added as current pair repair their processes.
UK-based Alliance Pharma reported a single-digit drop in Consumer Healthcare turnover ahead of a shareholder vote on the company's future ownership.
Industry’s results from October-December period start on 22 January with Procter & Gamble reporting its fiscal year 2025 second-quarter numbers and Abbott with its 2024 full-year and fourth-quarter information.
Major Europe-based consumer health players Haleon, Bayer and Reckitt feature in this sales and earnings preview, which highlights what to look out for as these three firms report their Q4 2024 results over the coming weeks.
PharmaSGP has added an additional €5m to the top-end of its sales guidance after recording a double-digit gain Italy and outpacing the growth of the OTC market in Germany.
A slowdown in China and the US, along with signs of a weaker cough & cold season in the latter, has led Bayer Consumer Health to lower its full-year sales guidance.
Finland is the latest market launch for OTC erectile dysfunction treatment Eroxon. High demand for the product in other countries, such as Norway, helped drive up Navamedic's consumer health sales in the first nine months of 2024.
“The infant formula business is recovering and we've taken actions to simplify and consumerize our business, but there's a lot more work to do,” says CEO Patrick Lockwood-Taylor as Perrigo’s announced latest results.
Firm’s future, as a separate business nearly 90% owned by Bausch Health, or as a standalone with different ownership or one not controlled by a majority owner, claims high profile in analysts’ comments and predictions. B+L is in the driver’s seat, they say.
Haleon highlighted consistent market share gains in China as it reported third-quarter results.
French public sector investment bank Bpifrance's influence over the future strategy of Opella extends to its one seat on the company's board, but not past that, Sanofi confirms as it reports Q3 results.
A better than expected showing from its Health business in its latest quarter has teed up Reckitt for a big finish to the year.
Kenvue may have to start sharing time with Bausch + Lomb in investors’ discussions about the outlook for success at US consumer health firms separated from former parent firms as they and their competitors begin reporting the results for their latest quarters.
Major Europe-based consumer health players Sanofi, Haleon, Reckitt and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q3 2024 results over the coming weeks.
An end to litigation filed by institutional investors, insurance companies and pension funds comes four CEOs after Perrigo's chief exec during Mylan's tender in 2015, Joseph Papa, resigned to lead another firm in 2016. Plaintiff attorneys are asking for up to 20% of settlement in fees.
Intensified competition in the dietary supplements market and consumers squeezed by cost-of-living pressures held back sales at Dermapharm's Arkopharma subsidiary in the first half. A leadership change, along with a renewed focus on commercial excellence, is hoped by Dermapharm to turn the business around.